Atypical femoral fractures (AFF) are related to long-term therapy with bisphosphonates in the setting of osteoporosis. This case study reviews the diagnosis and treatment of the condition.
Since fracture risk increases rapidly after denosumab discontinuation and multiple vertebral fractures occur with greater frequency, it is important to track patients who miss their scheduled injections. Rheumatologist Chad Deal, MD, explains.
Romosozumab, a dual-acting drug to treat osteoporosis, will be the No. 1 most influential medical innovation for 2020, predict experts at Cleveland Clinic.
Romosozumab, a dual-acting drug that increases bone formation and decreases resorption, received FDA approval. Rheumatologist Chad Deal, MD, discusses the related clinical trials and which patients make good candidates for this medication.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Osteoporosis is underdiagnosed. In this article, Dr. Pelin Batur discusses risk assessments and screening threshold recommendations for treatment and injury prevention.
Romosozumab-aqqg may give postmenopausal women an additional option for osteoporosis treatment when other medications are contraindicated. Women’s health specialist Holly Thacker, MD, explains the benefits and potential risks of this new regimen.
In this Q&A, Dr. Thacker helps physicians understand today’s osteoporosis prevention strategies.
In this series with three seriously ill patients, a vertebral stabilization technique dramatically decreased pain and increased function in the immediate postoperative period.
Can calcium and vitamin d supplementation adequately treat most patients with osteoporosis? Chad Deal, MD, weighs the evidence.
T-scores are necessary to establish the diagnosis of osteoporosis and to estimate disease prevalence, but they should not be used as the sole determinant to make treatment decisions in an individual.